STOCK TITAN

Evolus to Report Second Quarter 2021 Results and Provide Business Update

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Evolus, a performance beauty company, will announce its second quarter 2021 financial results on August 4, 2021, after U.S. market close. A conference call will follow at 4:30 p.m. ET, including a Q&A session. Interested participants can join the call by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international) and via their Investor Relations webpage. Evolus is known for its FDA-approved aesthetic neurotoxin, Jeuveau®, which aims to transform the beauty market. For more information, visit www.evolus.com.

Positive
  • None.
Negative
  • None.

NEWPORT BEACH, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its second quarter 2021 financial results and provide a business update on Wednesday, August 4, 2021, after the close of the U.S. financial markets.

Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of the Evolus website at www.evolus.com.

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international). An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com.

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investor Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: +1-949-966-1798
Email: IR@Evolus.com

Media Contact:
Crystal Muilenburg, Evolus, Inc.
Chief Marketing Officer
Tel: +1-949-284-4506
Email: media@evolus.com


FAQ

When will Evolus report its second quarter 2021 financial results?

Evolus will report its second quarter 2021 financial results on August 4, 2021.

What time is the Evolus conference call on August 4, 2021?

The Evolus conference call is scheduled for 4:30 p.m. ET on August 4, 2021.

How can I participate in the Evolus conference call?

To participate in the Evolus conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international), or connect via the Investor Relations page on Evolus' website.

What product is Evolus known for?

Evolus is known for its FDA-approved neurotoxin, Jeuveau®, dedicated exclusively to aesthetics.

Where can I find more information about Evolus?

More information about Evolus can be found on their website at www.evolus.com.

Evolus, Inc.

NASDAQ:EOLS

EOLS Rankings

EOLS Latest News

EOLS Stock Data

687.04M
50.17M
12.31%
80.25%
8.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
NEWPORT BEACH